Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Director departure Quarterly results Acq. announced Appointed director
|
|
TherapeuticsMD, Inc. (TXMD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/05/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Quarterly results |
| 03/10/2022 |
8-K
| Quarterly results |
| 11/12/2021 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer - Mr. O’Dowd to succeed Robert G. Finizio, effective on or before December 31, 2021 -",
"TherapeuticsMD Announces Third Quarter 2021 Financial Results - Quarterly total net product revenue of $24.5 million, an increase of 41.1% over Q3 2020 - - ANNOVERA ® TRx of 8,351, an increase of 62.7% over Q3 2020 -",
"TherapeuticsMD, Inc. Presentation" |
|
| 08/04/2021 |
8-K
| Investor presentation, Quarterly results |
| 05/06/2021 |
8-K
| Quarterly results |
| 03/02/2021 |
8-K
| Quarterly results |
| 11/09/2020 |
8-K
| Investor presentation, Quarterly results |
| 08/06/2020 |
8-K
| Quarterly results |
| 05/06/2020 |
8-K
| Quarterly results |
| 02/20/2020 |
8-K
| Quarterly results |
| 11/06/2019 |
8-K
| Investor presentation, Quarterly results |
| 08/06/2019 |
8-K
| Quarterly results |
| 05/06/2019 |
8-K
| Investor presentation, Quarterly results |
| 02/21/2019 |
8-K
| Quarterly results |
| 05/06/2014 |
8-K
| Investor presentation |
| 04/08/2014 |
8-K
| Investor presentation |
| 03/04/2014 |
8-K
| Investor presentation |
| 10/07/2013 |
8-K
| Investor presentation |
| 06/03/2013 |
8-K
| Investor presentation |
|
|